Update membranous nephropathy
Membranous nephropathy is an autoimmune disease caused in most cases by binding of circulating antibodies to antigens on podocytes. PLA R1 and THSD7A have been identified as target antigens in 70-80 % and 2-3 % of patients, respectively. The detection of PLA R1- and THSD7A-antibodies in the blood an...
Saved in:
| Published in: | Deutsche medizinische Wochenschrift (1946) Vol. 145; no. 20; p. 1481 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | German |
| Published: |
Germany
01.10.2020
|
| Subjects: | |
| ISSN: | 1439-4413, 1439-4413 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Membranous nephropathy is an autoimmune disease caused in most cases by binding of circulating antibodies to antigens on podocytes. PLA
R1 and THSD7A have been identified as target antigens in 70-80 % and 2-3 % of patients, respectively. The detection of PLA
R1- and THSD7A-antibodies in the blood and staining of renal biopsies for the respective antigens allow the correct diagnosis of PLA
R1- and THSD7A-associated membranous nephropathy, respectively, in practically 100 % of cases. Measurement of PLA
R1- and THSD7A-antibodies is helpful in order to further individualize the decision whether to perform a renal biopsy in patients with suspected membranous nephropathy. PLA
R1-antibody level is a strong predictor for remission of proteinuria, loss of renal function and relapse of disease. Moreover, treatment decisions in patients with PLA
R1-associated MN are increasingly based on the PLA
R1-antibody levels. Rituximab was shown to be non-inferior to ciclosporine A to induce remission of proteinuria after 12 months. After 24 months rituximab was superior to ciclosporine A for the same endpoint. Development of novel treatment strategies, focusing on disease pathogenesis, remains highly relevant for these patients. |
|---|---|
| AbstractList | Membranous nephropathy is an autoimmune disease caused in most cases by binding of circulating antibodies to antigens on podocytes. PLA
R1 and THSD7A have been identified as target antigens in 70-80 % and 2-3 % of patients, respectively. The detection of PLA
R1- and THSD7A-antibodies in the blood and staining of renal biopsies for the respective antigens allow the correct diagnosis of PLA
R1- and THSD7A-associated membranous nephropathy, respectively, in practically 100 % of cases. Measurement of PLA
R1- and THSD7A-antibodies is helpful in order to further individualize the decision whether to perform a renal biopsy in patients with suspected membranous nephropathy. PLA
R1-antibody level is a strong predictor for remission of proteinuria, loss of renal function and relapse of disease. Moreover, treatment decisions in patients with PLA
R1-associated MN are increasingly based on the PLA
R1-antibody levels. Rituximab was shown to be non-inferior to ciclosporine A to induce remission of proteinuria after 12 months. After 24 months rituximab was superior to ciclosporine A for the same endpoint. Development of novel treatment strategies, focusing on disease pathogenesis, remains highly relevant for these patients. Membranous nephropathy is an autoimmune disease caused in most cases by binding of circulating antibodies to antigens on podocytes. PLA2R1 and THSD7A have been identified as target antigens in 70-80 % and 2-3 % of patients, respectively. The detection of PLA2R1- and THSD7A-antibodies in the blood and staining of renal biopsies for the respective antigens allow the correct diagnosis of PLA2R1- and THSD7A-associated membranous nephropathy, respectively, in practically 100 % of cases. Measurement of PLA2R1- and THSD7A-antibodies is helpful in order to further individualize the decision whether to perform a renal biopsy in patients with suspected membranous nephropathy. PLA2R1-antibody level is a strong predictor for remission of proteinuria, loss of renal function and relapse of disease. Moreover, treatment decisions in patients with PLA2R1-associated MN are increasingly based on the PLA2R1-antibody levels. Rituximab was shown to be non-inferior to ciclosporine A to induce remission of proteinuria after 12 months. After 24 months rituximab was superior to ciclosporine A for the same endpoint. Development of novel treatment strategies, focusing on disease pathogenesis, remains highly relevant for these patients.Membranous nephropathy is an autoimmune disease caused in most cases by binding of circulating antibodies to antigens on podocytes. PLA2R1 and THSD7A have been identified as target antigens in 70-80 % and 2-3 % of patients, respectively. The detection of PLA2R1- and THSD7A-antibodies in the blood and staining of renal biopsies for the respective antigens allow the correct diagnosis of PLA2R1- and THSD7A-associated membranous nephropathy, respectively, in practically 100 % of cases. Measurement of PLA2R1- and THSD7A-antibodies is helpful in order to further individualize the decision whether to perform a renal biopsy in patients with suspected membranous nephropathy. PLA2R1-antibody level is a strong predictor for remission of proteinuria, loss of renal function and relapse of disease. Moreover, treatment decisions in patients with PLA2R1-associated MN are increasingly based on the PLA2R1-antibody levels. Rituximab was shown to be non-inferior to ciclosporine A to induce remission of proteinuria after 12 months. After 24 months rituximab was superior to ciclosporine A for the same endpoint. Development of novel treatment strategies, focusing on disease pathogenesis, remains highly relevant for these patients. |
| Author | Huber, Tobias B Hoxha, Elion |
| Author_xml | – sequence: 1 givenname: Elion surname: Hoxha fullname: Hoxha, Elion organization: lll. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf – sequence: 2 givenname: Tobias B surname: Huber fullname: Huber, Tobias B organization: lll. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33022730$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNjztLA0EUhQeJaIxW1kpKm9F53HmVEnxBwMbUy92ZGxLYnR33UeTfGzCC1TnFx8c5V2yWu0yM3UrxKIUxT8hFcJZ7H_QZm0vQgQNIPfvXL9il1kIpp8Wc3W1KwpGWLbV1j7mbhmWmsuu7guPucM3Ot9gMdHPKBdu8vnyt3vn68-1j9bzmRYIcOaLzFrEWqaboHUZAbX0CMAIoqYSQKJkYCElqHZR31m6DjbVGbyySWrCHX2_pu--JhrFq90OkpsFMx0mVAgjSBefNEb0_oVPdUqpKv2-xP1R_l9QPhfdLMg |
| ContentType | Journal Article |
| Copyright | Thieme. All rights reserved. |
| Copyright_xml | – notice: Thieme. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1055/a-0976-8893 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| DocumentTitleAlternate | Update membranöse Glomerulonephritis |
| EISSN | 1439-4413 |
| ExternalDocumentID | 33022730 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-p141t-aa786aab0dbec87ac4a368d44504ed2da4ded5c9eae133928766f96cb3a856ae2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000575428400010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1439-4413 |
| IngestDate | Fri Jul 11 06:43:28 EDT 2025 Thu Jan 02 22:57:54 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 20 |
| Language | German |
| License | Thieme. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p141t-aa786aab0dbec87ac4a368d44504ed2da4ded5c9eae133928766f96cb3a856ae2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 33022730 |
| PQID | 2449179785 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2449179785 pubmed_primary_33022730 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-00 20201001 |
| PublicationDateYYYYMMDD | 2020-10-01 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | Deutsche medizinische Wochenschrift (1946) |
| PublicationTitleAlternate | Dtsch Med Wochenschr |
| PublicationYear | 2020 |
| Score | 2.2226648 |
| Snippet | Membranous nephropathy is an autoimmune disease caused in most cases by binding of circulating antibodies to antigens on podocytes. PLA
R1 and THSD7A have been... Membranous nephropathy is an autoimmune disease caused in most cases by binding of circulating antibodies to antigens on podocytes. PLA2R1 and THSD7A have been... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1481 |
| SubjectTerms | Autoantibodies - blood Glomerulonephritis, Membranous - diagnosis Glomerulonephritis, Membranous - immunology Glomerulonephritis, Membranous - pathology Glomerulonephritis, Membranous - therapy Humans Immunologic Factors - therapeutic use Kidney Glomerulus - immunology Kidney Glomerulus - pathology Proteinuria Receptors, Phospholipase A2 - immunology Rituximab - therapeutic use Thrombospondins - immunology |
| Title | Update membranous nephropathy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33022730 https://www.proquest.com/docview/2449179785 |
| Volume | 145 |
| WOSCitedRecordID | wos000575428400010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qPXjxga-qlRW8hqabxyYnEbF40NKDhd6W2c0EPHS72iL4753sbvEkCF5yC2SSyXzzZTIzjN0GQJO5VHPCYsEVBs-JRtAgY_U1wq8yNInCz9lkYudzN-0e3Fbdt8qNTWwMtV-W8Y18SDBEzII4j76r33nsGhWjq10LjW3Wk-TKRK3O5k32m4oBTjLQXUqe0HoIXBD2cmtjkPk3d7KBlfHBfxd0yPY7hzK5bzXgiG15PGaDWR2ZfLLABbHhWIU1qbCOHRHI4fs6YbPx4-vDE-8aIfB6pEZrDpBZA1AITztuMygVSGO9Uloo9KkH5dHr0iEgUU5HJMiY4ExZSLDaAKanbKdaVnjOEikLDaktiiAKBSo4LNGIENIMBQrv-uxmI21OihajB1AhLTP_kbfPztoty-u2IkYuZaxEKMXFH2Zfsr00ctbmQ9wV6wW6Zjhgu-Xn-m31cd2cII2T6cs3mzSnqA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Update+membranous+nephropathy&rft.jtitle=Deutsche+medizinische+Wochenschrift+%281946%29&rft.au=Hoxha%2C+Elion&rft.au=Huber%2C+Tobias+B&rft.date=2020-10-01&rft.eissn=1439-4413&rft.volume=145&rft.issue=20&rft.spage=1481&rft_id=info:doi/10.1055%2Fa-0976-8893&rft_id=info%3Apmid%2F33022730&rft_id=info%3Apmid%2F33022730&rft.externalDocID=33022730 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1439-4413&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1439-4413&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1439-4413&client=summon |